GEN Exclusives

More »

GEN News Highlights

More »
Mar 14, 2007

Neuromed Banks $2M Milestone Payment from Merck & Co.

  • Neuromed Pharmaceuticals received a milestone payment of $2 million under its collaboration and license agreement with Merck & Co. In March 2006, the companies partnered to research, develop, and commercialize N-type calcium channel blockers for the treatment of pain and other disorders.

    "N-type calcium channels are an important target for pain,” states Christopher Gallen, president and CEO of Neuromed.  “Merck's commitment to this program gives it the highest chance to succeed in producing therapeutics for chronic pain and other underserved markets. "



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?